China-based biotech LianBio (OTCMKTS: LIANY) announced that enrollment has been completed in the Phase III EXPLORER-CN clinical trial, assessing mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
Drug Background
Mavacamten, discovered by MyoKardia Inc. (Nasdaq: MYOK), is a first-in-class small-molecule drug that reversibly binds to myosin. It targets the excess contractility and impaired relaxation underlying hypertrophic cardiomyopathy (HCM). LianBio entered into a license agreement with MyoKardia for the drug in 2020, paying USD40 million upfront and up to USD147.5 million in sales and regulatory milestones.
Study Details
The EXPLORER-CN study (NCT05174416 / CTR20212890) is a multicenter, double-blind, randomized, placebo-controlled registrational trial. It is designed to evaluate the safety and efficacy of mavacamten in Chinese patients with symptomatic oHCM. The primary endpoint is the change in Valsalva left ventricular outflow tract (LVOT) gradient from baseline to week 30. Topline results are anticipated in mid-2023, and positive outcomes could lead to the first market approval filing.-Fineline Info & Tech
